Bristol Myers Squibb’s Opdivo was recently granted FDA approval in combination with cisplatin and gemcitabine as a first-line treatment for metastatic urothelial carcinoma. With this approval, Opdivo positions itself to compete with Merck & Co’s immune checkpoint inhibitor Keytruda in combination with Astellas and Pfizer’s Padcev, a nectin-4-directed antibody-drug conjugate, according to GlobalData.
Tag Archive for: gemcitabine
The company’s blockbuster cancer drug continues to snap up FDA approvals, this time in treating biliary tract cancer in combination with cisplatin and gemcitabine.
Junshi Biosciences’ Neotorch is the world’s first registered Phase III immuno-oncology trial for lung cancer to post positive EFS (event-free survival) data.
